Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program

Enrollment complete in Phase 3 TrustTSC trial with topline data anticipated in the first half of Q4 2024 USPTO grants additional method of use patent for ganaxolone in TSC RADNOR, Pa.–(BUSINESS WIRE)–Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced completion of enrollment in … [Read more…]

Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia

IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ recharge-free sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder. “Approval of the Axonics recharge-free system is welcome news for Australians with bladder and bowel dysfunction,” said … [Read more…]

Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update

TWYMEEG® gross sales in Japan for Sumitomo Pharma Fiscal Year 20231 reached JPY 4.6 billion (EUR 27.9 million)2, exceeding guidance3 by more than 8% TWYMEEG®’s FY 2024 forecast4 of JPY 11.3 billion (EUR 69.1 million2) would represent a 150% increase over FY2023 sales Exclusive advanced discussions with a leading investor to monetize royalties from sales … [Read more…]

athenahealth Launching New Suite of Tailored Specialty Solutions to Simplify the Practice of Healthcare in America

New solutions pair tailored product enhancements to industry-leading athenaOne® platform with expert support; dedicated solutions for women’s health and urgent care available now BOSTON–(BUSINESS WIRE)–athenahealth, a leading provider of network-enabled software and services for medical groups and health systems nationwide, today announced the availability of athenaOne for Women’s Health and athenaOne for Urgent Care, as … [Read more…]

High-Cost Drugs Fuel ‘Unsustainable’ Surge in Prescription Spend for Employers

Nomi Health analysis highlights the urgent need for cost-management solutions amid escalating healthcare expenses OREM, Utah–(BUSINESS WIRE)–Prescriptions now constitute about a quarter of total benefit spending in the United States, costing employers exponentially more every year and accelerating at a rate nearly four times faster than overall medical spend from 2022 to 2023, according to … [Read more…]

LINNER Nova Deluxe: First Single MEMS Driver Audio Solution Powered by USound

A new model of OTC hearing aids by LINNER is now available in the United States. LINNER Nova Deluxe is the first single MEMS driver audio solution on the market, an achievement that was accomplished by utilizing USound’s MEMS technology. GRAZ, Austria–(BUSINESS WIRE)–#MEMS—USound, the leading global provider of MEMS speakers, announced the availability of the … [Read more…]

Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

95.7% of patients responded to Breyanzi in the TRANSCEND FL trial Breyanzi provided sustained clinical benefit with median duration of response not reached and the majority (77.1%) of responders in ongoing response at 18 months Breyanzi is a personalized therapy with a differentiated profile, offering durable responses and a consistent safety profile across trials PRINCETON, … [Read more…]

New Award Programme From Oral-B and the International Association for Disability and Oral Health (iADH) Champions Disability Positive Dental Practices Across Europe

Over a third (36%) of disabled people feel anxious or frustrated when it comes to visiting the dentist1 As the #1 recommended toothbrush brand by dentists worldwide, Oral-B is dedicated to transforming the dental office experience for people with disabilities into a more positive one Oral-B launches The Disability Champions Award Programme for dental staff … [Read more…]

Omeros Corporation Reports First Quarter 2024 Financial Results

– Conference Call Today at 4:30 p.m. ET SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results … [Read more…]